Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Update

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the recipient of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 2,203,718 shares, a growth of 212.0% from the February 12th total of 706,392 shares. Based on an average daily trading volume, of 6,530,944 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.3% of the shares of the company are short sold. Currently, 3.3% of the shares of the company are short sold. Based on an average daily trading volume, of 6,530,944 shares, the days-to-cover ratio is presently 0.3 days.

Klotho Neurosciences Trading Down 0.0%

Klotho Neurosciences stock traded down $0.00 during mid-day trading on Wednesday, hitting $0.52. The company’s stock had a trading volume of 2,219,377 shares, compared to its average volume of 3,792,310. The stock’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.45. Klotho Neurosciences has a 1 year low of $0.11 and a 1 year high of $3.91. The firm has a market capitalization of $38.23 million, a PE ratio of -1.62 and a beta of 9.08.

Institutional Trading of Klotho Neurosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd raised its stake in shares of Klotho Neurosciences by 101.2% during the fourth quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after purchasing an additional 80,768 shares during the last quarter. Geode Capital Management LLC grew its stake in Klotho Neurosciences by 51.8% in the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after acquiring an additional 167,905 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Klotho Neurosciences during the 4th quarter valued at about $126,000. Jane Street Group LLC purchased a new position in Klotho Neurosciences during the 4th quarter valued at about $64,000. Finally, Brummer Multi Strategy AB acquired a new position in shares of Klotho Neurosciences during the 4th quarter worth approximately $175,000. Institutional investors and hedge funds own 20.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on KLTO shares. Wall Street Zen upgraded Klotho Neurosciences to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.